Abstract:Background CD4+CD25+Foxp3+ T regulatory (Treg) cells play a key role in peripheral tolerance. Rapamycin was approved by the FDA to preserve renal allografts and to be efficacious in patients with several autoimmune diseases [1]. Objectives To investigate the status of Treg cells in active refractory rheumatoid arthritis (RA) and the effects of rapamycin on patients with RA. Methods Forty-five active refractory RA patients were enrolled. Rapamycin was used at a dose of 0.5 mg every 2 days [the preliminary, open-label clinical trial of rapamycin (Clinical Trials.gov number: ChiCTR-IPR-17010307)]. Clinical improvement and immunological assessments were performed before 1st rapamycin dose and 12 weeks post treatment. Blood samples were obtained from RA patients and 75 healthy volunteers for estimation of CD4+ T cell subsets. Results Two patients dropped out due to non-compliance. As compared to healthy controls (median of Treg cells: 33.32 cell/ul), the absolute counts of circulating Treg cells were significantly decreased in patients with active refractory RA (median: 27.17 cell/ul; P=0.046). While the median ratios of Th17/Treg cells in patients with active refractory RA (median: 0.26) were significantly higher than those of healthy volunteers (median: 0.19; P=0.029). No difference in the absolute counts of circulating Th17 cells and Th1 cells was observed between patients with active refractory RA and healthy subjects. Rapamycin treatment led to clinical improvement with the median post-treatment DAS28-ESR decreasing when compared to baseline (from 4.19 to 3.78) in active refractory RA patients. Sixteen patients (16/43 patients, 37.21%) achieved an EULAR moderate response and 6 patients (6/43 patients, 13.95%) reached good response at week 12. Rapamycin administration resulted in an increase in the absolute counts of Treg cells in active refractory RA patients, from a median of 27.17 cell/ul (at week 0) to 37.57 cell/ul (at week 12) (P=0.041). The ratios of Th17/Treg cells shows a reduction from a median of 0.26 at baseline to 0.20 at week 12, but the difference is not significant (P =0.376). No significant difference was observed in the absolute counts of circulating Th17 and Th1 cells after rapamycin treatment. Interestingly, we observed that Treg cells increased before the complete remission of the disease (DAS28 score <2.6) in patients with active refractory RA. At week 12, the mean dose of prednisone which refractory RA patients were receiving decreased from 11.98 mg/d to 8.31 mg/d, with a dose reduced by ≥30% than that at baseline. The categories of DMARDs use were also reduced (P<0.05). No serious adverse events was observed during the 12-week period of rapamycin treatment. Conclusions Reduced absolute number of Treg cells was found in the patients with active refractory RA, indicating an imbalance between Th17 and Treg cells. Rapamycin elicits rapid improvement of disease activity via restoring circulating Treg cells numbers in patients with active refractory RA. References Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016. 12(3): 169–82. Disclosure of Interest None declared

Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation

AB0421 Rapamycin Reduces Disease Activity Through Restoring Regulatory T Cell Numbers in Patients with Active Refractory Rheumatoid Arthritis

THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis

FRI0063 Rapamycin Induces Remission in Patients with Refractory Rheumatoid Arthritis

AB0382 Rapamycin Selectively Increases Circulating Tregcellsand Maintain Remission of Patients with Rheumatoid Arthritis

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

SAT0261 Refractory Systemic Lupus Erythematosus is Mainly Associated with the Decreased Number of Regulatory T Cells and Low-Dose Il-2 Combined with Rapamycin Can Efficiently Recovery the Balance of Th17/regulatory T Cells

Rapamycin Ameliorates Experimental Autoimmune Uveoretinitis By Inhibiting Thl/Th2/Th17 Cells And Upregulating Cd4+Cd25+Foxp3 Regulatory T Cells

AB0376 Rapamycin induces remission in patients with newly diagnosed rheumatoid arthritis

Beneficial effects of rapamycin on endothelial function in systemic lupus erythematosus

Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis

MiR-146a Relieves Kidney Injury in Mice with Systemic Lupus Erythematosus Through Regulating NF-κB Pathway.

Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome

Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients

Regulating T Cell Population Alleviates SLE by Inhibiting mTORC1/C2 in MRL/lpr Mice

Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus

Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment

CD8+iTregs Mediate the Protective Effect of Rapamycin Against Graft Versus Host Disease in a Humanized Murine Model.

Rapamycin Protects Kidney Against Ischemia Reperfusion Injury Through Recruitment of NKT Cells.

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease